Materials And Methods Of Treating MHC-1-Opathy Risk Haplotypes
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsSahar Gelfman, Ann Ligocki, Giovanni Coppola, Aris Baras, Arden Moscati, Eli A. Stahl, Jack A. Kosmicki, Manuel Allen Revez Ferreira, Carmelo Romano
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods of treating subjects having an immune disorder by administering to the subject a therapeutically effective amount of an Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) inhibitor in combination with an HLA-A29 or HLA-B27 inhibitory nucleic acid molecule.
Claims36
A method of treating a subject having an immune disorder, the method comprising administering to the subject an Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) inhibitory nucleic acid molecule and:
- i) an HLA-A29 inhibitor inhibitory nucleic acid molecule and/or ii) an HLA-B27 inhibitory nucleic acid molecule.
3-10. (canceled)
14-15. (canceled)
20-26. (canceled)
28-35. (canceled)
39-43. (canceled)
A method of treating a subject having an MHC-I-opathy, the method comprising:
- performing or having performed an assay on a biological sample from the subject to determine whether the subject comprises:
- i) an HLA-A29 allele and/or an HLA-B27 allele;
- and
- ii) a functional Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) protein or a nucleic acid molecule encoding a functional ERAP2 protein;
- and
- administering to the subject a therapeutically effective amount of an ERAP2 inhibitor inhibitory nucleic acid molecule and an HLA-A29 inhibitor inhibitory nucleic acid molecule to the subject having the functional ERAP2 protein or the nucleic acid molecule encoding a functional ERAP2 protein, and having the HLA-A29 allele;
- or
- administering to the subject a therapeutically effective amount of an ERAP2 inhibitory nucleic acid molecule and an HLA-B27 inhibitory nucleic acid molecule to the subject having the functional ERAP2 protein or the nucleic acid molecule encoding a functional ERAP2 protein, and having the HLA-B27 allele;
- wherein the presence of both:
- i) the HLA-A29 allele and/or the HLA-B27 allele, and ii) the functional ERAP2 protein or the nucleic acid molecule encoding a functional ERAP2 protein, indicates that the subject is a candidate for treating the MHC-I-opathy by inhibiting ERAP2.
46-49. (canceled)
54-60. (canceled)
62-68. (canceled)
70-77. (canceled)
81-121. (canceled)
A method of treating a subject having Birdshot Chorioretinopathy (BSCR), the method comprising administering to the subject an Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) inhibitory nucleic acid molecule and an HLA-A29 inhibitory nucleic acid molecule.
A method of treating a subject having Birdshot Chorioretinopathy (BSCR), the method comprising:
- performing or having performed an assay on a biological sample from the subject to determine whether the subject comprises:
- i) an HLA-A29 allele;
- and
- ii) a functional Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) protein or a nucleic acid molecule encoding a functional ERAP2 protein;
- and
- administering to the subject a therapeutically effective amount of an ERAP2 inhibitory nucleic acid molecule and an HLA-A29 inhibitory nucleic acid molecule to the subject having the functional ERAP2 protein or the nucleic acid molecule encoding a functional ERAP2 protein, and having the HLA-A29 allele,
- wherein the presence of the HLA-A29 allele and the functional ERAP2 protein or the nucleic acid molecule encoding a functional ERAP2 protein, indicates that the subject is a candidate for treating the BSCR by inhibiting ERAP2 and HLA-A29.
Dependencies are inferred from the claim text.